| Business Summary | | Genencor
International,
Inc.
is
a
diversified
biotechnology
company
that
develops
and
delivers
products
and/or
services
to
the
industrial
and
consumer,
agriculture
and
healthcare
markets.
The
Company
develops
products
that
deliver
solutions
using
an
integrated
set
of
technology
platforms,
including
gene
discovery
and
functional
genomics,
molecular
evolution
and
design
and
human
immunology.
The
Company
markets
and
sells
over
250
products
that
are
distributed
to
over
500
customers
in
over
80
countries.
The
Company
groups
its
marketed
products
into
three
general
functional
categories,
consisting
of
enzymes
that
break
down
protein,
starch
or
cellulose.
These
enzyme
products
are
marketed
for
fabric
care,
including
cleaning
and
textile
processing,
as
well
as
the
personal
care
market.
In
addition,
the
Company
markets
these
classes
of
enzymes
in
the
grain
processing
and
specialties
areas
of
the
agriculture
market. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Genencor
Int'l,
Inc.
is
engaged
in
the
development
of
genetically
based
biotech.
products,
using
technologies
such
as
gene
discovery
and
functional
genomics,
molecular
evolution
and
design,
and
human
immunology.
For
the
six
months
ended
6/30/01,
revenues
fell
less
than
1%
to
$159.1
million.
Net
income
applicable
to
Com.
fell
62%
to
$6.7
million.
Revenues
reflect
decreased
fees
and
royalties.
Earnings
also
suffered
from
increased
investments
in
technology
and
product
development. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| W. Thomas Mitchell, 55 Chairman,
Pres, CEO | $754K | $966K | Raymond Land, 56 Sr.
VP, CFO | 633K | 242K | Richard Ranieri, 49 Sr.
VP of HR | 590K | 242K | Michael Arbige, Ph.D., 46 Sr.
VP, Technology | 303K | 242K | Carole Cobb, 43 Sr.
VP, Global Supply | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|